Table 1 Clinical characteristics of study population before rituximab therapy
Characteristics | Patients (n = 24) |
|---|---|
Age at onset of disease, years | 18.88±8.57 (3-46) |
Age at first rituximab infusion, years | 23.58±7.89 (18-46) |
Male gender | 24 (100%) |
Disease duration, years | 4.29 (0.25-14.58) |
24h urinary protein excretion, g | 9.49±7.55 |
Serum creatinine, μmol/L | 118.58±109.24 |
eGFR (MDRD), ml/min*1.73m2 | 103.36±43.83 |
Serum albumin, g/L | 22.57±6.94 |
CD19+ B cell count, n/μL | 343.89±269.75 |
Previous immunosuppressive therapy | 62 |
 Long term corticosteroids | 22 |
 Cyclosporine | 11 |
 Tacrolimus | 12 |
 Cyclophosphamide | 1 |
 Mycophenolate mofetil | 8 |
 Chlorambucil | 4 |
 Leflunomide | 1 |
 Tripterygium glycosides | 3 |
Prednisone dose before rituximab therapy, mg/day | 28.15 (5-50) |
Relapse rate before rituximab therapy, number/year | 1.43 (0-4.36) |
Follow-up time, months | 14.71 (8-36) |